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Background: Transport protein particle (TRAPP) is a multiprotein complex involved in endoplasmic reticulum-to-Golgi
trafficking. Zebrafish with a mutation in the TRAPPC11 orthologue showed hepatomegaly with steatosis and defects in
visual system development. In humans, TRAPPC11 mutations have been reported in only three families
showing limb-girdle muscular dystrophy (LGMD) or myopathy with movement disorders and intellectual
disability.
Methods: We screened muscular dystrophy genes using next-generation sequencing and performed
associated molecular and biochemical analyses in a patient with fatty liver and cataract in addition to
infantile-onset muscle weakness.
Results: We identified the first Asian patient with TRAPPC11 mutations. Muscle pathology demonstrated typical
dystrophic changes and liver biopsy revealed steatosis. The patient carried compound heterozygous mutations
of a previously reported missense and a novel splice-site mutation. The splice-site change produced two
aberrantly-spliced transcripts that were both predicted to result in translational frameshift and truncated
proteins. Full-length TRAPPC11 protein was undetectable on immunoblotting.
Conclusion: This report widens the phenotype of TRAPPC11-opathy as the patient showed the following: (1) congenital
muscular dystrophy phenotype rather than LGMD; (2) steatosis and infantile-onset cataract, both not observed in
previously reported patients; but (3) no ataxia or abnormal movement, clearly indicating that TRAPPC11 plays a
physiological role in multiple tissues in human.
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Congenital muscular dystrophyBackground
Transport protein particle (TRAPP) is a multiprotein
complex involved in endoplasmic reticulum (ER)-to-
Golgi trafficking and possibly other membrane traffick-
ing steps [1, 2]. Oligomerization of TRAPP can give rise
to complexes with variable components in any one of* Correspondence: satomi11@me.com
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article, unless otherwise stated.several positions and might allow for a combinatorial
diversification of TRAPP function, perhaps regulating
cell-specific activities [3]. A loss-of-function mutation in
the zebrafish TRAPPC11 orthologue is characterized by
hepatomegaly with steatosis, thereby named foie gras
mutant, and by defects in visual system development
[4, 5]. In human, there has been only one report of
TRAPPC11 mutations, describing one Syrian family with
limb-girdle muscular dystrophy (LGMD) phenotype,
which was labeled LGMD2S, and two families of Hutterite
ancestry with myopathy phenotype, movement disor-
ders and intellectual disability [6]. In addition to im-
paired TRAPP assembly and disrupted Golgi apparatusis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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glycoproteins lysosome-associated membrane protein 1
(LAMP1) and LAMP2 were also observed in the cells of
affected individuals, suggesting a defect in the transport
of secretory proteins as the underlying pathomechanism.
We herein report the first Asian patient carrying com-
pound heterozygous mutations in the TRAPPC11 gene
who developed congenital muscular dystrophy (CMD)
phenotype with prominent fatty liver and infantile-onset
cataract, further broadening the clinical phenotype of
TRAPPC11-opathy.Case presentation
Clinical and pathological features
The currently 8-year-old Han Chinese girl residing in
Taiwan, born to non-consanguineous parents, was found
unable to stand up at age 1 year. Timeline of the devel-
opmental milestones before then was not recalled by the
parents. She started walking independently at age 1 year
and 6 months and readily fell down. At age 2 years,
speech delay was noticed as she could not speak any sig-
nificant single word though she could understand and
follow simple orders. Bilateral cataracts were also found
at the same age. Her birth history was uneventful, and
there was no relevant family history. However, rehabili-
tation did not show marked improvement in her speech
and motor functions. At age 3 years and 6 months, high
levels of transaminases were found immediately prior to
cataract surgery. Subsequently high creatine kinase (CK)
level was identified resulting in a referral to a pediatric
myologist. Physical examination showed mild lordosis,
positive Gowers’ sign with waddling gait, and decreased
deep tendon reflexes, as well as hepatomegaly. Neither
ataxia nor abnormal movement was observed. Blood
biochemistry indicated that the levels of AST (180 IU/L;
normal <40), ALT (1577 IU/L; normal <40), and serum
CK (8699 IU/L; normal: <175) were markedly elevated.
Further assessment identified borderline cognitive func-
tion (Bayley-II: mental developmental quotient scoreFig. 1 Brain and muscle imaging. a Mildly reduced periventricular white m
(T2-weighted flair). b Gluteal muscles were most affected on muscle CT as(DQ) = 82–87; motor DQ = 67). Brain magnetic reson-
ance imaging (MRI) did not show cerebral or cerebellar
atrophy, and there was no structural abnormality except
for slightly reduced periventricular white matter volume
with angular-shaped ventricles (Fig. 1a). On muscle
CT, posterior compartment of lower extremities were
preferentially involved and gluteal muscles were severely
affected (Fig. 1b).
Due to persistent high levels of AST/ALT and hepato-
megaly, liver biopsy was performed and revealed excessive
lipid accumulation in hepatic cells, suggestive of steatohe-
patitis (Fig. 2a). Muscle biopsy of the biceps brachii
revealed dystrophic change with scattered necrotic and
regenerating fibers and moderate endomysial fibrosis
(Fig. 2b) and mildly increased lipid droplets in the cyto-
plasm of muscle fibers on oil red O staining compared to
age-matched control (Fig. 2c). No notable abnormality
was shown on immunohistochemistry using the antibodies
against C-terminal, N-terminal, and core domain of
dystrophin (Novocastra Lab.), alpha-, beta-, delta-, and
gamma- sarcoglycans(Novocastra Lab.), alpha-(Upstate)
and beta-dystroglycans(Novocastra Lab.), merosin(Chemi-
con International), collagen VI(ICN Biomedicals, Inc),
dysferlin(Novocastra Lab.), caveolin-3(Transduction Lab.),
and emerin(Novocastra Lab.). In the subsequent 4-year
follow-up, her muscle weakness remained stationary. To
date, no cardiac or respiratory problems were found.Molecular and protein analyses
In order to identify the cause of this syndrome, targeted
next-generation sequencing covering reported muscu-
lar dystrophy related genes (AGRN, ALG13, ANO5,
B3GALNT2, B3GNT1, CAPN3, CAV3, CHKB, COL12A1,
COL6A1, COL6A2, COL6A3, DAG1, DES, DMD, DNAJB6,
DOK7, DOLK, DPAGT1, DPM1, DPM2, DPM3, DYSF,
EMD, FAT1, FHL1, FKRP, FKTN, FLNC, GFPT1, GMPPB,
ISPD, ITGA7, KLHL9, LAMA2, LARGE, LMNA, MEGF10,
MICU1, MYOT, PLEC, POMGNT1, POMGNT2, POMT1,
POMT2, PTRF, SGCA, SGCB, SGCD, SGCG, POMK,atter volume with angular-shaped ventricles was shown on brain MRI
the arrows indicate. (R right, L left)
Fig. 2 Liver and muscle pathology. a Hematoxylin and eosin staining (H&E) of liver biopsy showed marked lipid accumulation consistent with
steatohepatitis. (size bar 20 μm) H&E and oil red O staining of the biopsied muscle revealed dystrophic change (b) and mild lipid accumulation
(c). (size bar 50 μm for b and 20 μm for c)
Fig. 3 Molecular and protein analyses. a Sanger sequencing confirmed the compound heterozygous mutations c.661-1G > T and c.2938G > A in
TRAPPC11. b Analysis of skeletal muscle cDNA flanking exons 6 and 7 of TRAPPC11 showed two mutant transcripts (1 and 2) in addition to the
234-bp normal amplicon. c The novel c.661-1G > T splice-site mutation results in two mutant transcripts; mutant 1 with a truncated exon 7, and
mutant 2 with both truncated exon 7 and a cryptic exon in intron 6, both of which are predicted to cause translational frameshift, p.Leu240Alafs*10
and p.Leu240Valfs*7, respectively. Altered amino acids are in bold. d Protein analysis using the biopsied muscle revealed the absence of TRAPPC11
protein at 130 kDa while TRAPPC2 and tubulin were comparable to control muscle
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TMEM5, TNPO3, TRAPPC11, TRIM32) was performed on
genomic DNA extracted from blood lymphocytes of the
proband. Multiplex primer pools were designed using Ion
AmpliSeq™ Designer software (Life Technologies). This
custom gene panel covers 96.8 % of the coding sequence
region of these genes. Enrichment of exonic se-
quences was performed with Ion AmpliSeq™ Library
Kit 2.0 (Thermo Scientific) and sequenced on an
IonPGM™ (Thermo Scientific) according to the man-
ufacturer’s protocol. Compound heterozygous muta-
tions of c.2938G > T (p.Gly980Arg) and c.661-1G > T in
TRAPPC11 (NM_021942.5) were identified. Subsequent
Sanger sequencing of genomic DNA was performed in
both the proband and her parents to confirm the detected
variants (Fig. 3a). This revealed that c.2938G > T was
found in the father and c.661-1G > T in the mother. Since
the c.661-1G > T mutation suggested there might be
a splicing defect, further cDNA analysis with Super-
Script VILO Master Mix Kit (Life Technologies) for
the c.661-1G > T mutation was carried out to investi-
gate illegitimate splicing. The forward primer in exon 5
(5′- TTGTTTGTACTGCCGCACAC-3′) and the reverse
primer flanking the end of exon 7 and the beginning
of exon 8 (5′- GGTCCTATAATTCTTCAGCGCATT-3′)
generate a 234-bp amplicon from the wild-type TRAPPC11
cDNA sequence. RT-PCR products were then cloned into
the pCR4 TOPO-TA vector (Invitrogen) to allow detection
of all mRNA products by sequencing with fluorescent
dideoxy chain terminators (Applied Biosystems, FosterTable 1 Comparison of the present patient and previously reported
c.2938G > A homoa c.12
Number of patient 3 5
Age of onset Early school age Early
Muscle symptoms Proximal weakness, myalgia, cramps Mild
Muscle pathology Myopathic (1)b Myo
CK (IU/L) 600~2800 300~
Head circumference Within normal limit <3rd
Intellectual disability (−) (+)
Ataxia (−) (+)
Choreiform movement (−) (+)
Other neurological problems (−) Gen
abno
Neuroimaging Not available Mild
Cardiac involvement Enlarged right ventricle (1)b (−)
Skeletal involvement Hip dysplasia, scoliosis Limb
Ocular involvement Esotropia and myopia (1)b cataract (1)b Exop
Hepatic involvement (−) (−)
aPreviously reported mutation (Ref 6)
bThe number of patient (if no number is indicated for the item, it means all patient
Homo homozygosity, EEG electroencephalogramCity, CA, USA) on an ABI 3130 sequencing instrument
(Applied Biosystems). Two additional aberrantly spliced
transcripts were identified, and both were predicted
to result in translational frameshift (Fig. 3b, c). In bi-
opsied muscle, immunoblotting procedures using
anti-TRAPPC11 (1:500), anti-TRAPPC2 (1:500), and anti-
tubulin (1:1000, DM1A, Sigma) as primary antibodies
were performed (the TRAPPC11 and TRAPPC2 anti-
bodies were noncommercial and raised against a peptide
derived from the carboxy-terminal region of TRAPPC11
and full-length His-tagged TRAPPC2) [3, 7]. Full-length
TRAPPC11 protein was not observed (Fig. 3d).
Discussion
We have demonstrated that the novel splice-site muta-
tion c.661-1G > T results in two different aberrant tran-
scripts, predicted to produce two truncated proteins.
The absence of a full-length TRAPPC11 protein by
Western blot analysis suggests the possibility that
Gly980Arg mutation may destabilize the protein, which
was also shown in the previous report describing
Gly980Arg in a homozygous manner, or may enhance its
degradation [6].
In the previous study, the affected individuals with
TRAPPC11 mutations presented with two groups of
clinical manifestations: one with more prominent mus-
cular and skeletal symptoms and the other with micro-
cephaly, hyperkinetic movements, ataxia, and intellectual
disability, apparently reflecting the difference of the
two genotypes, Gly980Arg and Ala372_Ser429del. Threepatients with TRAPPC11 mutations
87 + 5G > A homoa c.2938G > A/c.661-1G > T
1
childhood onset Around 1-year-old or even earlier







eralized seizure (1)b (−)
rmal EEG (2)b
cerebral atrophy (2)b Reduced white matter volume
(−)
asymmetry (1)b Lordosis
horia, anisometropia, and amblyopia (1)b Infantile—onset cataract
Steatosis
s presented with this feature
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and five affected members from two unrelated families
had homozygous Ala372_Ser429del. No notable interfa-
miliar difference of phenotype was observed between the
two families with Ala372_Ser429del mutation. Notewor-
thily, only one patient with Gly980Arg mutation was re-
ported to develop mild cataracts after school age.
Clinical manifestation of the patient in the present study
is different from the previously reported patients in sev-
eral respects. First, the patient in the present study pre-
sented with steatosis and very early-onset cataract,
similar to what was seen in the foie gras mutant in zeb-
rafish. Second, the patient developed a CMD phenotype
rather than the LGMD seen in the previous study. Fi-
nally, the patient does not display choreiform movement,
ataxia, nor any skeletal abnormality. These differences
may partly be explained by a more deleterious effect of
the splice-site mutation on the TRAPPC11 protein which
we expect to lead to complete loss of function, compared
to Gly980Arg or a 58 amino acid in-frame deletion in
homozygosity in the previous study. Table 1 summa-
rizes the phenotypic differences between the present
patient and previously reported patients with TRAPPC11
mutations.
It is noteworthy that, although the patient presented
here did not have microcephaly, abnormal involuntary
movements, nor cerebral atrophy, which were previously
reported in the patients with TRAPPC11 mutations [6],
her brain MRI at the age of 3 years and 6 months re-
vealed slightly reduced white matter volume. Reduced
white matter volume in pediatric patients is usually asso-
ciated with periventricular leukomalacia, the major sub-
strate of neurologic deficits in premature infants [8].
However, it might also be the consequence of diffuse
axonal damage or maldevelopment such as hypomyeli-
nation, which may not be easily differentiated by
imaging without serial studies [9, 10]. Regarding the nor-
mal maternal pregnancy and birth history of the patient
in this study, ischemic/hypoxic injury-causing white
matter volume loss seems unlikely. As the T1- and
T2-weighted images did not show notably abnormal
intensity, mild hypomyelination was thus considered.
Interestingly, the deficiency of a Golgi-associated protein,
dymeclin, was recently reported to cause postnatal
microcephaly, hypomelination, and ER-to-Golgi traffick-
ing defects in both mice and humans [11]. Although
dymeclin has not yet known to be a binding partner of
TRAPP complex, the similar Golgi-associated nature and
clinical phenotype are indicative of probable interaction
and common pathomechanism of these two proteins.
The present study also provides further supportive evi-
dence of the relationship between the impaired cellular
trafficking and brain phenotype in TRAPPC11-associated
disease.Conclusions
Collectively, this study widens the phenotype of
TRAPPC11-opathy. Although the detailed mechanism
causing intracellular lipid storage in liver is still un-
known, the phenotype of the patient in this study
clearly indicates that TRAPPC11 plays a physiological
role in multiple tissues in humans including the liver,
muscle, eye, brain, and bone. This may be due to impair-
ment of TRAPPC11 functions in multiple membrane-
trafficking pathways or other processes.
Consent
Written informed consent was obtained from the pa-
tient’s mother for publication of this Case Report and
any accompanying images. A copy of the written consent
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